Sesame Summit 2026 – application open

Scripta Therapeutics raises €10.3M in biotech seed funding

European biotech is experiencing a renaissance, with AI-driven drug discovery becoming the sector’s most compelling investment thesis. Against this backdrop, Oxford-based Scripta Therapeutics has secured €10.3 million in seed funding to revolutionise how pharmaceuticals approach early-stage drug development. The round, led by Oxford Science Enterprises and Apollo Health Ventures, signals growing European investor confidence in computational biology platforms that can compress traditional drug discovery timelines from decades to years.

What makes this particularly noteworthy is the European provenance of both the technology and the capital. While Silicon Valley often dominates biotech headlines, Scripta’s approach demonstrates how European research institutions can spawn commercially viable ventures that compete on the global stage.

Strategic investors back biotech seed funding innovation

Oxford Science Enterprises, the University of Oxford’s venture arm, co-leading this round represents more than institutional backing—it’s a validation of academic-to-commercial translation potential. Their investment thesis centres on technologies that emerge from world-class research environments and can scale to address global pharmaceutical challenges.

Apollo Health Ventures, known for backing European healthtech companies through complex regulatory landscapes, brings complementary expertise in navigating the intricate path from laboratory to market. Their portfolio strategy focuses on companies that leverage computational approaches to traditional life sciences problems.

“Scripta represents the next generation of drug discovery platforms,” noted a representative from Oxford Science Enterprises. “Their computational approach to identifying novel therapeutic targets aligns with our investment focus on companies that can fundamentally reshape how we approach medical innovation.”

The investor combination suggests this isn’t merely a technology play—it’s a strategic bet on European biotech’s ability to compete with established US platforms while navigating Europe’s distinct regulatory and commercial environment.

Computational drug discovery targets European pharma market

Scripta’s platform addresses a critical bottleneck in pharmaceutical development: the time and cost required to identify viable drug targets. Traditional approaches can take 10-15 years and cost billions, with high failure rates. Their computational methodology aims to compress these timelines while improving success probability.

The European pharmaceutical landscape presents both opportunities and challenges for platforms like Scripta’s. While the region hosts major pharmaceutical companies like Novartis, Roche, and Sanofi, it also maintains complex regulatory frameworks through the European Medicines Agency that require sophisticated navigation.

Founder statements suggest the funding will accelerate platform development and enable partnerships with European pharmaceutical companies seeking to enhance their early-stage discovery capabilities. This positions Scripta to capture value from the growing trend of big pharma outsourcing computational discovery to specialised platforms.

The timing proves fortuitous, as European pharmaceutical companies increasingly seek AI-driven solutions to maintain competitive advantage against US and Asian rivals. Recent studies indicate European pharma R&D spending reached record levels in 2024, creating expanded market opportunities for innovative discovery platforms.

This funding round exemplifies European biotech’s maturation—sophisticated computational platforms emerging from world-class research institutions, backed by investors who understand both the technology and the complex commercial landscape. For Scripta, the real test begins now: translating computational promise into therapeutic reality.

you might also like

Fundraising 4 hours ago

London-based AI laboratory Ineffable Intelligence has emerged from stealth with a $1.1 billion seed round at a $5.1 billion post-money valuation, the company confirmed on 27 April 2026. The financing is the largest seed round ever raised by a European company and one of the largest first-money-in rounds in the global history of artificial intelligence. The round was co-led by Sequoia Capital and Lightspeed Venture Partners. Participating investors included Nvidia, DST Global, Index Ventures, Google, and the UK Sovereign AI Fund, the British government’s recently established vehicle for backing strategic AI capacity on home soil. A bet on a different path to general intelligence Ineffable Intelligence was founded in 2025 by David Silver, the former Vice President of Reinforcement Learning at Google DeepMind and the principal architect of AlphaGo, AlphaZero and AlphaStar. He is joined by three further DeepMind alumni: Wojciech Czarnecki, Lasse Espeholt and Junhyuk Oh. All four have spent the past decade at the frontier of reinforcement learning research, the discipline behind some of the most consequential demonstrations of machine learning over the past ten years. The company describes its objective as building a “superlearner” — an AI system capable of acquiring knowledge directly from its own experience rather than from human-generated text or imagery. “Our mission is to make first contact with superintelligence,” Silver said in a statement accompanying the launch. “We are creating a superlearner that discovers all knowledge from its own experience, from elementary motor skills through to profound intellectual breakthroughs.” The framing is a deliberate departure from the dominant industry trajectory. Most leading AI laboratories, including OpenAI, Anthropic and Google DeepMind itself, have built large language models trained primarily on the corpus of the internet, then refined that training with human feedback. Ineffable’s wager is that the marginal returns on scaling text-based pretraining are diminishing and that the next leap in capability will come from agents that learn endlessly from the consequences of their own actions, in much the same way AlphaZero learnt the game of Go without studying any human matches. Why $1.1 billion at seed The size of the round is unusual even by the inflated standards of the 2026 AI capital cycle. Two factors appear to explain it. First, frontier reinforcement learning at the scale Ineffable describes is computationally extraordinarily expensive: the company will need to operate vast simulation environments and train very large models against them, an undertaking that consumes capital at a rate closer to physical R&D than to traditional software. Second, the round signals a strategic move by Europe’s investor and policy ecosystems to retain the most ambitious AI researchers on the continent. The presence of the UK Sovereign AI Fund alongside Sequoia, Lightspeed and Nvidia is the clearest expression of that intent. The British government has publicly framed the investment as a bet on breakthrough AI that “can discover new knowledge”, positioning the country as a willing co-investor in domestic frontier laboratories. For Ineffable, the implication is access not only to capital but to compute, regulatory engagement and the still-resilient academic talent base around UCL, Oxford, Cambridge and Imperial. Founder pledge of historic scale Alongside the funding announcement, Silver disclosed that he is committing 100 per cent of any personal proceeds from his Ineffable equity to charity via the Founders Pledge network — described by the organisation as the largest pledge in its history. At the round’s $5.1 billion valuation, that commitment could ultimately exceed several billion dollars if the company succeeds. It is a meaningful gesture in a sector where the reputational stakes around concentrated AI wealth are escalating, and one likely to be referenced in subsequent founder-led commitments. Implications for the European AI landscape Ineffable’s emergence reshapes the European AI map in three concrete ways. It establishes London as the home of the continent’s largest-ever seed-stage company, complicating Paris’s recent narrative of frontier-AI primacy after Mistral’s earlier rounds. It validates a thesis — that reinforcement learning, not transformer scaling, is the next frontier — that has lately been losing capital share to language-model incumbents. And it confirms that the UK government is now willing to act as a balance-sheet co-investor in domestic AI laboratories, a posture much closer to the French model than to the predominantly grant-based regimes elsewhere in Europe. The execution risk is non-trivial. Reinforcement learning at frontier scale has historically required years of careful environment design before producing competitive systems, and Ineffable’s “first contact” framing sets a high bar against which it will be judged. But for now, with a billion dollars on the balance sheet, four of the discipline’s most accomplished researchers in the founding team and a sovereign co-investor at its back, Ineffable Intelligence is the most heavily resourced new entrant in the European AI cycle. Sesamers covers European fundraising rounds across deeptech, fintech and AI. Source: tech.eu.

Fundraising 5 days ago

Belfast's Cloudsmith has raised $72M Series C led by TCV, with Insight Partners participating, to expand its artifact management platform and secure the AI-era software supply chain.

Fundraising 5 days ago

Berlin’s VREY has raised €3.3M seed led by Rubio Impact Ventures to roll out rooftop solar software for Germany’s multi-family buildings.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.